Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Operating Expenses Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual operating expenses in 2024 was 168.43 Million USD , down -0.66% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly operating expenses in 2024 FY was 168.43 Million USD , down -0.66% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a annual operating expenses of 169.55 Million USD in annual operating expenses 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported a annual operating expenses of 169.55 Million USD in annual operating expenses 2022, up 11.97% from previous year.
Xeris Biopharma Holdings, Inc. reported a quarterly operating expenses of 168.43 Million USD for 2024 FY, down -0.66% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a quarterly operating expenses of 46.2 Million USD for 2024 Q3, up 5.12% from previous quarter.

Annual Operating Expenses Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Operating Expenses of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2024	168.43 Million USD	-0.66%
2023	169.55 Million USD	0.0%
2022	169.55 Million USD	11.97%
2021	151.42 Million USD	60.46%
2020	94.37 Million USD	52.79%
2019	61.76 Million USD	119.18%
2018	28.18 Million USD	97.1%
2017	14.29 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	42.32 Million USD	-8.85%
2024 FY	168.43 Million USD	-0.66%
2024 Q3	46.2 Million USD	5.12%
2024 Q4	45.75 Million USD	-0.97%
2024 Q2	43.95 Million USD	3.85%
2023 FY	169.55 Million USD	0.0%
2023 Q4	46.43 Million USD	12.82%
2023 Q3	41.15 Million USD	-11.37%
2023 Q2	46.43 Million USD	7.37%
2023 Q1	43.24 Million USD	9.73%
2022 Q2	64.81 Million USD	101.45%
2022 Q1	32.17 Million USD	2.76%
2022 FY	169.55 Million USD	11.97%
2022 Q4	39.41 Million USD	-12.17%
2022 Q3	44.87 Million USD	-30.76%
2021 Q3	22.96 Million USD	-0.26%
2021 Q2	23.02 Million USD	13.09%
2021 FY	151.42 Million USD	60.46%
2021 Q1	20.36 Million USD	-11.22%
2021 Q4	31.31 Million USD	36.34%
2020 FY	94.37 Million USD	52.79%
2020 Q1	30.39 Million USD	-11.53%
2020 Q4	22.93 Million USD	-18.83%
2020 Q3	28.25 Million USD	-14.55%
2020 Q2	33.06 Million USD	8.77%
2019 Q2	21.11 Million USD	36.01%
2019 Q4	34.35 Million USD	33.76%
2019 FY	61.76 Million USD	119.18%
2019 Q1	15.52 Million USD	17.83%
2019 Q3	25.68 Million USD	21.64%
2018 Q2	9.67 Million USD	24.98%
2018 FY	28.18 Million USD	97.1%
2018 Q4	13.17 Million USD	10.25%
2018 Q3	11.95 Million USD	23.51%
2018 Q1	7.74 Million USD	34.41%
2017 Q3	5 Million USD	0.0%
2017 Q4	5.76 Million USD	15.13%
2017 FY	14.29 Million USD	0.0%

Peer Operating Expenses Comparison of Xeris Biopharma Holdings, Inc.

Name	Operating Expenses	Operating Expenses Difference
Arrowhead Pharmaceuticals, Inc.	445.73 Million USD	62.212%
Codexis, Inc.	66.51 Million USD	-153.219%
Viridian Therapeutics, Inc.	254.76 Million USD	33.885%
Organovo Holdings, Inc.	14.91 Million USD	-1029.306%